Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Ovarian Cancer
In Women with Relapsed Ovarian Cancer and BRCA Mutation, Olaparib Extends Survival by >1 Year
Read More
Ovarian Cancer
Patients with Newly Diagnosed Stage III or IV Ovarian Cancer and Atezolizumab
Read More
Ovarian Cancer
Subsequent Chemotherapy Following Olaparib Maintenance Therapy in BRCA1/2 Mutated Platinum-Sensitive Recurrent Epithelial Ovarian Cancer
Read More
Ovarian Cancer
Treatment Strategies and Survival in Women with Malignant Ovarian Germ Cell Tumors
Read More
Ovarian Cancer
Deleterious BRCA Mutations More Likely on Long-Term Responders to Rucaparib
Read More
Ovarian Cancer
In Patients with Ovarian Cancer and Non-BRCA HRR Gene Mutations, Promising Results Seen with Maintenance Rucaparib
Read More
Ovarian Cancer
Maintenance Therapy with Olaparib plus Bevacizumab in Newly Diagnosed Advanced High‐Grade Ovarian Carcinoma
Read More
Ovarian Cancer
Phase 3 ARIEL3 Study: Maintenance Treatment with Rucaparib for Recurrent Ovarian Cancer and Timing of Adverse Events
Read More
Ovarian Cancer
Real-World, Multinational ‘RESPONSE’ to Standard-of-Care Practices with PARP Inhibitors in Patients with Advanced Ovarian Cancer
Read More
Ovarian Cancer
In Patients with Advanced Ovarian Cancer, Olaparib/Bevacizumab as First-Line Maintenance Reduced the Risk of Progression or Death
Read More
1
2
3
Page 2 of 3
Results 11 - 20 of 27